Needham analyst Serge Belanger maintained a Hold rating on BioCryst (BCRX) on March 5. The company’s shares closed last Monday at $4.11.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.2% and a 37.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioCryst with a $7.33 average price target.
See today’s analyst top recommended stocks >>
Based on BioCryst’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $2.62 million. In comparison, last year the company had a GAAP net loss of $27.43 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
